BACKGROUND: We aimed to evaluate the Meningococcal (Neisseria meningitidis) C conjugated (MCC) vaccine seroconversion and adverse events (AEs) in HIV-infected and HIV-uninfected children and adolescents in Rio de Janeiro, Brazil. METHODS: HIV-infected or HIV-uninfected subjects, 2-18 years old, with CD4+ T-lymphocyte cell (CD4) percentage >15%, without active infection or antibiotic use, were enrolled. All patients were evaluated before and 1-2 months after immunization for seroconversion (defined as ≥4-fold titer increase in human serum bactericidal activity) and at 20 minutes, 3 and 7 days after immunization for AEs. Factors associated with seroconversion among HIV-infected group were studied. RESULTS: Two hundred four subjects were enrolled: 154 HIV-infected and 50 HIV-uninfected. Median age was 12 years, and 53% were female. Among the HIV-infected group, 82 (53%) had a history of at least 1 C clinical category of Centers for Diseases Control and Prevention event, and 134 (87%) were using combination antiretroviral therapy. The median nadir CD4 percentage was 13% (0-47%). Seventy-six (37.3%) experienced mild AEs. Seroconversion occurred in 46 of 154 (30%) in the HIV-infected group and in 38 of 50 (76%) in the uninfected group (P < 0.01). Factors associated with seroconversion in the HIV-infected group were as follows: never had a C clinical category event [odds ratio (OR) = 2.1, 95% confidence interval (CI): 1.0-4.4]; undetectable viral load at immunization (OR: 2.4, 95% CI: 1.1-5.2) and higher CD4 nadir/100 cells (OR: 1.1, 95% CI: 1.0-1.2). CONCLUSION: MCC vaccine should be administered to HIV-infected children and adolescents after maximum immunologic and virologic benefits have been achieved with combination antiretroviral therapy. Our data suggest that a single dose of MCC vaccine is insufficient for HIV-infected individuals 2-18 years of age.
BACKGROUND: We aimed to evaluate the Meningococcal (Neisseria meningitidis) C conjugated (MCC) vaccine seroconversion and adverse events (AEs) in HIV-infected and HIV-uninfectedchildren and adolescents in Rio de Janeiro, Brazil. METHODS:HIV-infected or HIV-uninfected subjects, 2-18 years old, with CD4+ T-lymphocyte cell (CD4) percentage >15%, without active infection or antibiotic use, were enrolled. All patients were evaluated before and 1-2 months after immunization for seroconversion (defined as ≥4-fold titer increase in human serum bactericidal activity) and at 20 minutes, 3 and 7 days after immunization for AEs. Factors associated with seroconversion among HIV-infected group were studied. RESULTS: Two hundred four subjects were enrolled: 154 HIV-infected and 50 HIV-uninfected. Median age was 12 years, and 53% were female. Among the HIV-infected group, 82 (53%) had a history of at least 1 C clinical category of Centers for Diseases Control and Prevention event, and 134 (87%) were using combination antiretroviral therapy. The median nadir CD4 percentage was 13% (0-47%). Seventy-six (37.3%) experienced mild AEs. Seroconversion occurred in 46 of 154 (30%) in the HIV-infected group and in 38 of 50 (76%) in the uninfected group (P < 0.01). Factors associated with seroconversion in the HIV-infected group were as follows: never had a C clinical category event [odds ratio (OR) = 2.1, 95% confidence interval (CI): 1.0-4.4]; undetectable viral load at immunization (OR: 2.4, 95% CI: 1.1-5.2) and higher CD4 nadir/100 cells (OR: 1.1, 95% CI: 1.0-1.2). CONCLUSION:MCC vaccine should be administered to HIV-infectedchildren and adolescents after maximum immunologic and virologic benefits have been achieved with combination antiretroviral therapy. Our data suggest that a single dose of MCC vaccine is insufficient for HIV-infected individuals 2-18 years of age.
Authors: Daniela Vinhas Bertolini; Luciana Scarlazzari Costa; Inneke Marie van der Heijden; Helena Keiko Sato; Heloísa Helena de Sousa Marques Journal: Vaccine Date: 2012-07-06 Impact factor: 3.641
Authors: Harry Keyserling; Thomas Papa; Katalin Koranyi; Robert Ryall; Ehab Bassily; Michael J Bybel; Kevin Sullivan; Gregory Gilmet; Al Reinhardt Journal: Arch Pediatr Adolesc Med Date: 2005-10
Authors: George K Siberry; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Patrick Jean-Philippe; Ram Yogev; Barbara E Heckman; Adam Manzella; Jhoanna Roa; Sharon Nachman; Jorge Lujan-Zilbermann Journal: Pediatr Infect Dis J Date: 2012-01 Impact factor: 2.129
Authors: Mark J Abzug; Stephen I Pelton; Lin-Ye Song; Terence Fenton; Myron J Levin; Sharon A Nachman; William Borkowsky; Howard M Rosenblatt; John F Marcinak; Arry Dieudonne; Elaine J Abrams; Indu Pathak Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Caroline L Trotter; Manosree Chandra; Rosa Cano; Amparo Larrauri; Mary E Ramsay; Carina Brehony; Keith A Jolley; Martin C J Maiden; Sigrid Heuberger; Matthias Frosch Journal: FEMS Microbiol Rev Date: 2006-12-01 Impact factor: 16.408
Authors: Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang Journal: Clin Infect Dis Date: 2014-02 Impact factor: 9.079
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Lucimar G Milagres; Priscilla R Costa; Giselle P Silva; Karina I Carvalho; Wânia F Pereira-Manfro; Bianca Ferreira; Daniella M Barreto; Ana Cristina C Frota; Cristina B Hofer; Esper G Kallas Journal: PLoS One Date: 2014-12-22 Impact factor: 3.240
Authors: Ruth D Simmons; Peter Kirwan; Kazim Beebeejaun; Andrew Riordan; Ray Borrow; Mary E Ramsay; Valerie Delpech; Samuel Lattimore; Shamez Ladhani Journal: BMC Med Date: 2015-12-09 Impact factor: 8.775
Authors: Giselle P Silva; Wania F Pereira-Manfro; Priscilla R Costa; Dayane A Costa; Bianca Ferreira; Daniela M Barreto; Ana Cristina C Frota; Cristina B Hofer; Carlos M Figueredo; Barbara Coelho; Esper G Kallas; Lucimar G Milagres Journal: Clinics (Sao Paulo) Date: 2021-10-01 Impact factor: 2.365